Allarity Therapeutics

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

BIOLASE

G Medical Innovations Holdings Ltd

Penumbra

ZyVersa Therapeutics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In August

LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Detsamma Investments Pty. Ltd. trading as “FivepHusion,” an advanced clinical-stage biotechnology company developing Deflexifol™, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV), announced today that the two companies have entered into a Clinical Collaboration Agreement. Under this agreement, Allarity will support FivepHusion's future clinical development of Deflexifol™ for the treatment of solid tumors by using certain of Allarity's drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic, to potentially select patients for enrollment and treatment in clinical trials of Deflexifol™ as a monotherapy and in combination with other drugs.

Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

New appointments bring therapeutic development expertise and proven leadership to support continu ed progress of Allarity's mult i ple oncology clinical programs BOSTON (July 24, 2023) — Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of three seasoned biotechnology executives, Laura Benjamin, Ph.D., Robert Oliver, M.B.A.

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allarity Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock (or common stock equivalents in lieu thereof) and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $4.50 per share, will be exercisable immediately and will expire five years from the initial exercise date.

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

Shares of clinical-stage precision medicine company Allarity Therapeutics (NASDAQ: ALLR ) initially soared to a 60% gain for the midweek session before paring down gains to roughly 30%. Undergirding sentiment was early-stage data evaluating the efficacy of Ixempra — a metastatic breast cancer therapeutic — at multiple sites in Europe.

Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?

Boston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA® in metastatic breast cancer (mBC) patients selected with the DRP®-IXEMPRA® companion diagnostic (CDx) candidate. Researchers prescreened mBC patients using Allarity's DRP®-IXEMPRA® CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP®-score, and those with scores above 67% were selected for treatment with IXEMPRA®.

Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on  June 2 9 , 2023 Press R elease BOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 40 pre-split shares. The reverse stock split will become effective at 4:05 p.m.

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is issuing this press release to clarify the effective date of its contemplated reverse stock split. The Company is clarifying that the reverse stock split will not be effected on June 27, 2023, and will continue to trade without giving effect to the proposed reverse stock split until further notice.

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

Meeting adjourned to  Friday, June 23 , 2023  at 1 :00 p .m. Eastern Time

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

Phase 2 study e valuating the u tility of a DRP ® c ompanion d iagnostic for cisplatin support s

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2023 / Recently, Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clinical-stage pharma company's metastatic breast cancer treatment. Already approved by the Food and Drug Administration (FDA) for patients in the United States, the company is sponsoring this current trial as part of its work to get IXEMPRA® and IXEMPRA-DRP® the companion diagnostic approved as a treatment in Europe.

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,869,330 shares of common stock, 7,130,670 pre-funded warrants, and 10,000,000 common warrants to purchase 10,000,000 shares of common stock at an effective combined price of $0.75 per share and common warrant for aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.85 per share, will be exercisable immediately and will expire five years from the initial exercise date.

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Allarity Therapeutics (NASDAQ: ALLR ) stock is falling hard on Wednesday after the clinical-stage pharmaceutical company launched a public offering. That public offering has the company selling up to $20 million in shares, as well as warrants to purchase its stock.

Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and dovitinib. The company is evaluating the safety, dosing, and potential therapeutic benefit of this combination therapy on advanced solid tumors, including ovarian cancer.

This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial

Novavax

Sangamo Therapeutics

Clover Health Investments

Helius Medical Technologies

Nektar Therapeutics

Vyne Therapeutics

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.

7 Sorry Pharma Stocks to Sell in April Before It's Too Late

FOR IMMEDIATE RELEASE Abstract Evaluating Allarity's DRP ® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP ® Companion Diagnostic for Cisplatin Response in Certain Breast Cancer Patients Boston, MA (April 11, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that an abstract on the Company's proprietary DRP® technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago.

Abstract Evaluating Allarity's DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer.

Allarity's stock falls after saying enrollment in two clinical trials is slow

Efforts underway to accelerate patient recruitment and a mend protocols

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post-split share for every 35 pre-split shares. The post Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect appeared first on Pulse 2.0.

News for Allarity Therapeutics Stock (ALLR)